Provided by Tiger Fintech (Singapore) Pte. Ltd.

I-MAB

0.6800
-0.0501-6.86%
Post-market: 0.77000.0900+13.24%19:58 EDT
Volume:585.98K
Turnover:378.15K
Market Cap:55.38M
PE:-0.89
High:0.7000
Open:0.6801
Low:0.5950
Close:0.7301
Loading ...

Company Profile

Company Name:
I-MAB
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
34
Office Location:
2440 Research Boulevard,Suite 400,Rockville,Maryland,United States
Zip Code:
20850
Fax:
- -
Introduction:
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Directors

Name
Position
Sean Xi Yong Fu
Chief Executive Officer,Director
Wei Fu
Chairman of the Board
Chun Kwok Alan Au
Independent Director
Conor Chia hung Yang
Independent Director
Lielie Zhang
Independent Director

Shareholders

Name
Position
Sean Xi Yong Fu
Chief Executive Officer,Director
Joseph Skelton
Chief Financial Officer
Phillip Dennis
Chief Medical Officer